Table 3 Open in new tab Multivariable...

All patients (N = 774)	Patients without extensive LGE (N = 708)
Model 1 with 2022 ESC risk factors	Model 1 with 2022 ESC risk factors
ESC Risk-SCD score	1.19 (1.10–1.29)	< .001	ESC Risk-SCD score	1.23 (1.10–1.37)	< .001
Apical aneurysm	2.58 (.34–19.71)	.360	Apical aneurysm	.00 (.00-inf)	.978
LVEF <50%	11.76 (5.47–25.27)	< .001	LVEF <50%	12.71 (5.00–32.28)	< .001
LGE ≥15%	2.88 (1.39–6.00)	.005	LGE ≥5%	7.07 (2.66–18.77)	< .001
Model 2 with 2020 AHA/ACC risk factors	Model 2 with 2020 AHA/ACC risk factors
Family history of SCD	1.65 (.72–3.80)	.238	Family history of SCD	2.03 (.64–6.47)	.232
MWT ≥30 mm	1.74 (.75–4.02)	.195	MWT ≥30 mm	1.82 (.66–5.03)	.247
Unexplained syncope	2.65 (1.34–5.26)	.005	Unexplained syncope	3.62 (1.60–8.22)	.002
Apical aneurysm	2.04 (.26–15.89)	.497	Apical aneurysm	.0 (.00-inf)	.980
LVEF <50%	8.30 (3.61–19.06)	< .001	LVEF <50%	11.10 (3.61–34.12)	< .001
Non-sustained VT	3.08 (1.60–5.94)	.001	NSVT	2.45 (.99–6.05)	.052
LGE ≥15%	2.75 (1.27–5.96)	.011	LGE ≥5%	6.19 (2.27–16.89)	< .001

All patients (N = 774)

Patients without extensive LGE (N = 708)

Model

HR (95% CI)

P-value

Model

HR (95% CI)

P-value

Model 1 with 2022 ESC risk factors

ESC Risk-SCD score

1.19 (1.10–1.29)

< .001

ESC Risk-SCD score

1.23 (1.10–1.37)

< .001

Apical aneurysm

2.58 (.34–19.71)

.360

Apical aneurysm

.00 (.00-inf)

.978

LVEF <50%

11.76 (5.47–25.27)

< .001

LVEF <50%

12.71 (5.00–32.28)

< .001

LGE ≥15%

2.88 (1.39–6.00)

.005

LGE ≥5%

7.07 (2.66–18.77)

< .001

Model 2 with 2020 AHA/ACC risk factors

Family history of SCD

1.65 (.72–3.80)

.238

Family history of SCD

2.03 (.64–6.47)

.232

MWT ≥30 mm

1.74 (.75–4.02)

.195

MWT ≥30 mm

1.82 (.66–5.03)

.247

Unexplained syncope

2.65 (1.34–5.26)

.005

Unexplained syncope

3.62 (1.60–8.22)

.002

Apical aneurysm

2.04 (.26–15.89)

.497

Apical aneurysm

.0 (.00-inf)

.980

LVEF <50%

8.30 (3.61–19.06)

< .001

LVEF <50%

11.10 (3.61–34.12)

< .001

Non-sustained VT

3.08 (1.60–5.94)

.001

NSVT

2.45 (.99–6.05)

.052

LGE ≥15%

2.75 (1.27–5.96)

.011

LGE ≥5%

6.19 (2.27–16.89)

< .001

All patients (N = 774)	Patients without extensive LGE (N = 708)
Model 1 with 2022 ESC risk factors	Model 1 with 2022 ESC risk factors
ESC Risk-SCD score	1.19 (1.10–1.29)	< .001	ESC Risk-SCD score	1.23 (1.10–1.37)	< .001
Apical aneurysm	2.58 (.34–19.71)	.360	Apical aneurysm	.00 (.00-inf)	.978
LVEF <50%	11.76 (5.47–25.27)	< .001	LVEF <50%	12.71 (5.00–32.28)	< .001
LGE ≥15%	2.88 (1.39–6.00)	.005	LGE ≥5%	7.07 (2.66–18.77)	< .001
Model 2 with 2020 AHA/ACC risk factors	Model 2 with 2020 AHA/ACC risk factors
Family history of SCD	1.65 (.72–3.80)	.238	Family history of SCD	2.03 (.64–6.47)	.232
MWT ≥30 mm	1.74 (.75–4.02)	.195	MWT ≥30 mm	1.82 (.66–5.03)	.247
Unexplained syncope	2.65 (1.34–5.26)	.005	Unexplained syncope	3.62 (1.60–8.22)	.002
Apical aneurysm	2.04 (.26–15.89)	.497	Apical aneurysm	.0 (.00-inf)	.980
LVEF <50%	8.30 (3.61–19.06)	< .001	LVEF <50%	11.10 (3.61–34.12)	< .001
Non-sustained VT	3.08 (1.60–5.94)	.001	NSVT	2.45 (.99–6.05)	.052
LGE ≥15%	2.75 (1.27–5.96)	.011	LGE ≥5%	6.19 (2.27–16.89)	< .001

Table 3

Open in new tab

Multivariable Cox regression analysis for guideline-based risk factors in predicting SCD-related events

All patients (N = 774)			Patients without extensive LGE (N = 708)
Model	HR (95% CI)	P-value	Model	HR (95% CI)	P-value
Model 1 with 2022 ESC risk factors			Model 1 with 2022 ESC risk factors
ESC Risk-SCD score	1.19 (1.10–1.29)	< .001	ESC Risk-SCD score	1.23 (1.10–1.37)	< .001
Apical aneurysm	2.58 (.34–19.71)	.360	Apical aneurysm	.00 (.00-inf)	.978
LVEF <50%	11.76 (5.47–25.27)	< .001	LVEF <50%	12.71 (5.00–32.28)	< .001
LGE ≥15%	2.88 (1.39–6.00)	.005	LGE ≥5%	7.07 (2.66–18.77)	< .001
Model 2 with 2020 AHA/ACC risk factors			Model 2 with 2020 AHA/ACC risk factors
Family history of SCD	1.65 (.72–3.80)	.238	Family history of SCD	2.03 (.64–6.47)	.232
MWT ≥30 mm	1.74 (.75–4.02)	.195	MWT ≥30 mm	1.82 (.66–5.03)	.247
Unexplained syncope	2.65 (1.34–5.26)	.005	Unexplained syncope	3.62 (1.60–8.22)	.002
Apical aneurysm	2.04 (.26–15.89)	.497	Apical aneurysm	.0 (.00-inf)	.980
LVEF <50%	8.30 (3.61–19.06)	< .001	LVEF <50%	11.10 (3.61–34.12)	< .001
Non-sustained VT	3.08 (1.60–5.94)	.001	NSVT	2.45 (.99–6.05)	.052
LGE ≥15%	2.75 (1.27–5.96)	.011	LGE ≥5%	6.19 (2.27–16.89)	< .001

All patients (N = 774)			Patients without extensive LGE (N = 708)
Model	HR (95% CI)	P-value	Model	HR (95% CI)	P-value
Model 1 with 2022 ESC risk factors			Model 1 with 2022 ESC risk factors
ESC Risk-SCD score	1.19 (1.10–1.29)	< .001	ESC Risk-SCD score	1.23 (1.10–1.37)	< .001
Apical aneurysm	2.58 (.34–19.71)	.360	Apical aneurysm	.00 (.00-inf)	.978
LVEF <50%	11.76 (5.47–25.27)	< .001	LVEF <50%	12.71 (5.00–32.28)	< .001
LGE ≥15%	2.88 (1.39–6.00)	.005	LGE ≥5%	7.07 (2.66–18.77)	< .001
Model 2 with 2020 AHA/ACC risk factors			Model 2 with 2020 AHA/ACC risk factors
Family history of SCD	1.65 (.72–3.80)	.238	Family history of SCD	2.03 (.64–6.47)	.232
MWT ≥30 mm	1.74 (.75–4.02)	.195	MWT ≥30 mm	1.82 (.66–5.03)	.247
Unexplained syncope	2.65 (1.34–5.26)	.005	Unexplained syncope	3.62 (1.60–8.22)	.002
Apical aneurysm	2.04 (.26–15.89)	.497	Apical aneurysm	.0 (.00-inf)	.980
LVEF <50%	8.30 (3.61–19.06)	< .001	LVEF <50%	11.10 (3.61–34.12)	< .001
Non-sustained VT	3.08 (1.60–5.94)	.001	NSVT	2.45 (.99–6.05)	.052
LGE ≥15%	2.75 (1.27–5.96)	.011	LGE ≥5%	6.19 (2.27–16.89)	< .001

Bold values indicate statistical significance. SCD, sudden cardiac death; LGE, late gadolinium enhancement; HR, hazard ratio; CI, confidence interval; ESC, European Society of Cardiology; LVEF, left ventricular ejection fraction; AHA, American Heart Association; ACC, American College of Cardiology; MWT, maximal wall thickness; VT, ventricular tachycardia.

This Feature Is Available To Subscribers Only